
Abbvie acquires Cerevel Therapeutics
James Spargo | August 2, 2024 | News story | Mergers and Acquisitions | AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson’s disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.
Cerevel has multiple programmes across neurological and psychiatric conditions such as schizophrenia, Parkinson’s disease and mood disorders. One example is emraclidine, a next-generation antipsychotic positive allosteric modulator (PAM) of the muscarinic M4 receptor, indicated for the treatment of schizophrenia. There is also tavapadon, a dopamine D1/D5 selective partial agonist for the management of Parkinson’s disease, which is currently in phase 3 studies.
Darigabat, an alpha 2/3/5 selective GABAA receptor PAM for the treatment-resistant epilepsy and panic disorder, is currently in phase 2, and CVL-354 – a kappa opioid receptor (KOR) antagonist currently in phase 1 – has the potential to provide improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD).
“Abbvie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond,” said Robert A Michael, chief executive officer, AbbVie. “Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie.”
James Spargo
2/8/24
Related Content

Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Researchers at King Abdullah University of Science and Technology (KAUST) and the University of Oxford …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan
EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical …






